We’ve packed this issue with insights and actionable takeaways. You’ll find timely updates, helpful resources, and important reminders — all designed to support our collaborative mission of exceptional pediatric care. This month’s highlights include:
Delaware’s Birth to Three Early Intervention Program supports families with infants and toddlers who have or are at risk of developmental delays or disabilities. The program’s mission is to empower parents and caregivers by providing comprehensive resources and services tailored to each child’s unique needs.
Respiratory syncytial virus (RSV) is a widespread respiratory virus that poses serious health risks for infants and young children. To combat this, the Centers for Disease Control and Prevention (CDC) now recommends RSFP immunization to help prevent severe RSV disease. This can be achieved through maternal vaccination or the administration of the RSV monoclonal antibody (nirsevimab) to infants.
In September 2024, the U.S. Food and Drug Administration (FDA) granted approval for FluMist, the nasal spray influenza vaccine, to be administered by individuals themselves or by caregivers. This new option provides a safe and effective alternative of receiving the seasonal influenza vaccine, offering increased convenience and flexibility for families.
